Back to top
more

Becton, Dickinson and Company (BDX)

(Real Time Quote from BATS)

$234.59 USD

234.59
183,443

+1.44 (0.62%)

Updated Apr 19, 2024 10:43 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.

Here's Why You Should Hold BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

BD's (BDX) slew of product launches and strategic deals raises optimism about the stock.

BD's (BDX) Latest Product to Offer Wider Access to Researchers

by Zacks Equity Research

The latest worldwide commercial availability of BD's (BDX) cell sorters is set to expand researchers' capabilities to transform research and cell-based therapeutic development across numerous fields.

Why Becton Dickinson (BDX) is a Top Value Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

BDX vs. MMSI: Which Stock Is the Better Value Option?

by Zacks Equity Research

BDX vs. MMSI: Which Stock Is the Better Value Option?

AngioDynamics (ANGO) Settles Patent Litigations With BD

by Zacks Equity Research

AngioDynamics (ANGO) announces its settlement agreement with BD's affiliate, C.R. Bard, to resolve a 10-year dispute over outstanding patent litigation.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

QIAGEN (QGEN) Partners With IPPA to Raise TB Screening Awareness

by Zacks Equity Research

QIAGEN's (QGEN) collaboration with IPPA follows the updated CDC guidelines for TB screening for immigrants in the United States.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

BD's (BDX) ADC System Favored by New Study for Long-Term Care

by Zacks Equity Research

BD's (BDX) ADC system is likely to result in improvements in clinical workflow, operational efficiency and financial savings in long-term care facilities.

Here's Why You Should Retain BD (BDX) to Your Portfolio

by Zacks Equity Research

BD's (BDX) slew of product launches raises optimism about the stock.

BD (BDX) Initiates IDE Study to Aid Treatment of Artery Disease

by Zacks Equity Research

BD (BDX) commences the enrollment of the first patient in the IDE study for the assessment of the company's Vascular Covered Stent for the treatment of Peripheral Arterial Disease.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

BD (BDX), Camtech Health Unite to Aid Cervical Cancer Screening

by Zacks Equity Research

BD (BDX) collaborates with Camtech Health to improve the rate of cervical cancer screening in Singapore by offering women an option to self-collect samples in the privacy of their own homes.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

BDX or WST: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

BDX vs. WST: Which Stock Is the Better Value Option?

The Zacks Analyst Blog Highlights Thermo Fisher Scientific, Philip Morris, General Dynamics, Becton, Dickinson, Cheniere Energy and Aflac

by Zacks Equity Research

Thermo Fisher Scientific, Philip Morris, General Dynamics, Becton, Dickinson, Cheniere Energy and Aflac are included in this Analyst Blog.

Sheraz Mian headshot

Earnings Season Scorecard and Analyst Reports for Thermo Fisher, Philip Morris & General Dynamics

by Sheraz Mian

Today's Research Daily features the real-time earnings season scorecard and updated analyst reports on Thermo Fisher (TMO), Philip Morris International (PM) and General Dynamics (GD).

Three Reasons to Retain BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

BD's (BDX) slew of product launches raises optimism about the stock.

BD (BDX) Q1 Earnings Surpass Estimates, Margins Contract

by Zacks Equity Research

BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal first quarter.

Becton Dickinson (BDX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Becton Dickinson (BDX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Becton Dickinson (BDX) Q1 Earnings Surpass Estimates

by Zacks Equity Research

Becton Dickinson (BDX) delivered earnings and revenue surprises of 12.13% and 0.64%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Conmed (CNMD) Lags Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Conmed (CNMD) delivered earnings and revenue surprises of -4.51% and 1.77%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

BD's (BDX) Tie-Up to Offer AI-Based Digital System for Pap Test

by Zacks Equity Research

BD's (BDX) latest partnership is likely to aid cytotechnologists and pathologists to efficiently identify evidence of cervical cancer and pre-cancerous lesions.

Debanjana Dey headshot

Medical Device Stocks' Earnings on Feb 1: RVTY, CAH & More

by Debanjana Dey

Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how CAH, RVTY, CNMD, SRDX and BDX are placed ahead of their earnings releases.

BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited fiscal first-quarter sales.